腎細胞癌のための上市薬とパイプライン薬市場：薬剤価、臨床試験、ソーシャルメディアと競合情勢

当レポートでは、世界の腎細胞癌のための上市薬とパイプライン薬市場について調査し、疾患の概要とともに、作用機序別、投与経路別、分子タイプ別の市販薬、パイプライン薬の評価、臨床試験動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 調査結果

第3章 疾患概要

• 疾患概要
• 疫学概要
• 治療概要

第4章 市販薬評価

• 主要な市販薬
• 作用機序別概要
• 投与経路別概要
• 分子タイプ別概要
• 市販薬のプロファイルと売上予測

第5章 パイプライン薬剤品評価

• 後期パイプライン薬
• 開発段階別概要
• 作用機序別概要
• 投与経路別概要
• 分子タイプ別概要
• 薬剤固有の相転移成功率（PTSR）と承認可能性（LoA）
• 治療領域と適応症別のPTSRおよびLoA

第6章 臨床試験評価

• 歴史的概要
• 相別の概要
• ステータス別の概要
• 進行中および計画中の試験の相別の概要
• 仮想コンポーネントを使用した臨床試験
• 地理的概要
• 地域別の単一国および多国籍試験
• 相別の内訳を持つ上位20の治験依頼者
• ステータス別の内訳を持つ上位20の治験依頼者
• エンドポイントステータス別の概要
• 人種および民族別の概要
• 登録データ
• 試験場所の上位20か国
• 世界の上位20サイト
• 実現可能性分析-地理的概要
• 実現可能性分析-ベンチマークモデル

第7章 取引情勢

• 地域別の合併、買収、戦略的提携
• 最近の合併、買収、および戦略的提携

第8章 商業的評価

• 主要な市場参入企業

第9章 将来の市場促進要因

第10章 付録

This reports provides a data-driven overview of the current and future competitive landscape in Renal Cell Carcinomar therapeutics.

Synopsis

In 2022, there will be more than 1,490,000 diagnosed prevalent cases of renal cell carcinoma across 16 pharmaceutical markets.

There are 10 leading marketed drugs for the treatment of renal cell carcinoma, Merck is a key player in the disease space.

The renal cell carcinoma pipeline consists of 338 pharmaceuticals spanning all stages of development, with approximately 40% of drugs in mid to late-stage development.

Non-commercial sponsors dominate clinical trial development in renal cell carcinoma, with the US emerging as the key countries for conducting trials in renal cell carcinoma.

Deals involving partnerships are the most common type of deals globally.

Therapeutic options for renal cell carcinoma patients continue to be limited, with only one new therapy expected to reach the US market in the next 18 months.

Scope

GlobalData's Renal Cell Carcinoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

Disease Landscape

Disease Overview

Epidemiology Overview

Treatment Overview

Marketed Products Assessment

Breakdown by Mechanism of Action, Molecule Type and Route of Administration

Product Profiles with Sales Forecast

Pipeline Assessment

Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

Late-to-mid-stage Pipeline Drugs

Phase Transition Success Rate and Likelihood of Approval

Clinical Trials Assessment

Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

Enrolment Analytics, Site Analytics, Feasibility Analysis

Deals Landscape

Mergers, Acquisitions, and Strategic Alliances by Region

Overview of Recent Deals

Commercial Assessment

Key Market Players

Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Renal Cell Carcinomar market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Renal Cell Carcinomar market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations
• 2 Key Findings
• 3 Disease Landscape
• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview
• 4 Marketed Drugs Assessment
• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Overview by Molecule Type
• 4.5 Marketed Drugs Profiles and Sales Forecasts
• 5 Pipeline Drugs Assessment
• 5.1 Late-stage Pipeline Drugs
• 5.2 Overview by Development Stage
• 5.3 Overview by Mechanism of Action
• 5.4 Overview by Route of Administration
• 5.5 Overview by Molecule Type
• 5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 5.7 Therapy Area and Indication-specific PTSR and LoA
• 6 Clinical Trials Assessment
• 6.1 Historical Overview
• 6.2 Overview by Phase
• 6.3 Overview by Status
• 6.4 Overview by Phase for Ongoing and Planned Trials
• 6.5 Trials with Virtual Components
• 6.6 Geographic Overview
• 6.7 Single-Country and Multinational Trials by Region
• 6.8 Top 20 Sponsors with Breakdown by Phase
• 6.9 Top 20 Sponsors with Breakdown by Status
• 6.10 Overview by Endpoint Status
• 6.11 Overview by Race and Ethnicity
• 6.12 Enrollment Data
• 6.13 Top 20 countries for Trial Sites
• 6.14 Top 20 Sites Globally
• 6.15 Feasibility Analysis - Geographic Overview
• 6.16 Feasibility Analysis - Benchmark Models
• 7 Deals Landscape
• 7.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 7.2 Recent Mergers, Acquisitions, and Strategic Alliances
• 8 Commercial Assessment
• 8.1 Key Market Players

9 Future Market Catalysts

10 Appendix

• 10.1 Methodology
• 10.2 Methodology - PTSR and LoA Analysis
• 10.3 About the Authors
• 10.4 Contact Us
• 10.5 Disclaimer